Department of Health Policy and Informatics, Graduate School of Medicine, Institute of Science Tokyo, Tokyo, Japan.
Department of Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Cochrane Database Syst Rev. 2024 Oct 30;10(10):CD015169. doi: 10.1002/14651858.CD015169.
This is a protocol for a Cochrane Review (intervention). The objectives are as follows: Primary objective: to assess the benefits and harms of currently recommended regimens as the first-line therapy in high-risk people with chronic lymphocytic leukemia, using network meta-analysis Secondary objectives: to assess whether the benefits and harms of the recommended regimens differ according to sex, Rai stage, or genetic mutation status to estimate the ranking of treatments for overall survival, progression-free survival, objective response rate, complete response rate, minimal residual disease, and serious adverse events to estimate the overall rate of adverse events and serious adverse events.
这是一篇 Cochrane 综述（干预措施）的方案。其目的如下：
使用网络荟萃分析评估目前推荐的方案作为慢性淋巴细胞白血病高危人群一线治疗的疗效和安全性。
评估推荐方案的疗效和安全性是否因性别、Rai 分期或基因突变状态而异，以估计总生存、无进展生存、客观缓解率、完全缓解率、微小残留病和严重不良事件的治疗排序。
估计不良事件和严重不良事件的总发生率。
